RxDoctor Payments Data

Eileen Javellana, MD

Internal Medicine · Gainesville, GANPI 1003896952

Payments from drug & device makers

$495in general payments, 2019–2025

Across 18 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$172
  • Lilly USA, LLC$125
  • Astellas Pharma US Inc$80
  • GSK$43
  • Boston Scientific$17
  • Sanofi Pasteur Inc.$16
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$495100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$495 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$47,604
Medicare patients
154
Services billed
1,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin42$45,068
MounjaroTirzepatide40$43,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$30,592
EliquisApixaban28$30,302
FarxigaDapagliflozin Propanediol32$24,713
JanuviaSitagliptin Phosphate23$18,712
OzempicSemaglutide18$16,911
JanumetSitagliptin Phos/Metformin Hcl19$13,910
Sucralfate13$2,737
Duloxetine Hcl118$1,775
Nifedipine ErNifedipine45$1,674
Levothyroxine Sodium196$1,429
Dapsone15$1,387
Famotidine80$1,321
Rosuvastatin Calcium90$1,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$125$43,04140 claims
GSKTrelegy Ellipta$43$30,59242 claims
Novo NordiskOzempic$172$16,91118 claims
AbbVieSynthroid$15$46813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →